Legend Biotech Corporation will hold its Annual General Meeting on October 21, 2024, at 9:30 a.m. at their Somerset, New Jersey office. Key proposals include re-electing four Class I directors for three-year terms and ratifying Ernst & Young LLP as the independent auditor for FY2024.A significant proposal seeks shareholder approval to increase the 2020 Restricted Shares Plan reserve by 15 million ordinary shares, bringing the total to 26 million shares. The company cites expansion of manufacturing and commercial capabilities for CARVYKTI®, along with ongoing R&D activities, as reasons for the increase. As of August 31, 2024, only 1.89 million shares remained available for grants.The Board believes the additional shares will provide sufficient equity awards for 2-4 years, with an expected burn rate of approximately 1.1%. The increase represents 4.1% of fully diluted ordinary shares and aims to support new hiring while maintaining competitive compensation for current employees.

Legend Biotech Corporation will hold its Annual General Meeting on October 21, 2024, at 9:30 a.m. at their Somerset, New Jersey office. Key proposals include re-electing four Class I directors for three-year terms and ratifying Ernst & Young LLP as the independent auditor for FY2024.A significant proposal seeks shareholder approval to increase the 2020 Restricted Shares Plan reserve by 15 million ordinary shares, bringing the total to 26 million shares. The company cites expansion of manufacturing and commercial capabilities for CARVYKTI®, along with ongoing R&D activities, as reasons for the increase. As of August 31, 2024, only 1.89 million shares remained available for grants.The Board believes the additional shares will provide sufficient equity awards for 2-4 years, with an expected burn rate of approximately 1.1%. The increase represents 4.1% of fully diluted ordinary shares and aims to support new hiring while maintaining competitive compensation for current employees.